FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA finds no faults with self-administration for the hereditary angioedema drug as it takes the new molecular entity to a June 23 advisory panel.